Ardsley Advisory Partners’s Amicus Therapeutics FOLD Stock Holding History

Ardsley Advisory Partners’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-15,000	Closed	-$212K	–	161
2020 Q3	$212K	Sell	15,000 -240,000	-94%	-$3.5M	0.04%	127
2020 Q2	$3.85M	Buy	+255,000	New	+$3.11M	0.82%	33
2019 Q3	–	Sell	-22,500	Closed	-$281K	–	152
2019 Q2	$281K	Buy	22,500 +2,500	+13%	+$31.7K	0.04%	117
2019 Q1	$272K	Sell	20,000 -195,000	-91%	-$2.38M	0.05%	106
2018 Q4	$2.06M	Sell	215,000 -295,000	-58%	-$3.24M	0.52%	39
2018 Q3	$6.17M	Buy	510,000 +5,000	+1%	+$69.9K	0.83%	37
2018 Q2	$7.89M	Buy	505,000 +70,000	+16%	+$1.06M	1.19%	33
2018 Q1	$6.54M	Buy	435,000 +105,000	+32%	+$1.6M	0.98%	38
2017 Q4	$4.75M	Sell	330,000 -35,000	-10%	-$481K	0.58%	44
2017 Q3	$5.5M	Buy	+365,000	New	+$4.83M	0.73%	47
2016 Q4	–	Sell	-225,000	Closed	-$1.67M	–	147
2016 Q3	$1.67M	Buy	+225,000	New	+$1.52M	0.26%	67

Other funds holding FOLD

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ardsley Advisory Partners's FOLD Position: Q4 2020 in Review

Ardsley Advisory Partners sold out of Amicus Therapeutics (FOLD) in Q4 2020, closing a stake of 15,000 shares — an estimated $212K sold.

Ardsley Advisory Partners first reported a position in FOLD in Q3 2016 and held it in 11 quarters. The position peaked at $7.89M in Q2 2018. 272 funds tracked by Wall St. Rank hold FOLD as of Q4 2020.

Ardsley Advisory Partners reported no remaining Amicus Therapeutics position as of Q4 2020 after selling out during the quarter.
Ardsley Advisory Partners sold 15,000 Amicus Therapeutics shares in Q4 2020, an estimated $212K.
Ardsley Advisory Partners first reported a position in Amicus Therapeutics in Q3 2016 and held it in 11 quarters.
Ardsley Advisory Partners's Amicus Therapeutics position peaked at $7.89M in Q2 2018.
272 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2020.

Based on Ardsley Advisory Partners's 13F filing for Q4 2020, filed 16 Feb 2021.